Pritelivir mesylate is under clinical development by AiCuris Anti-infective Cures and currently in Phase III for Simplexvirus (HSV) Infections. According to GlobalData, Phase III drugs for Simplexvirus (HSV) Infections have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Pritelivir mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pritelivir mesylate overview
Pritelivir mesylate (AIC-316, BAY-571293) is under development for the treatment of genital herpes type 2 infection (HSV-2) and herpes labialis. The therapeutic candidate is administered orally, topically and through vaginal routes. It is a compound derived from a chemical class of thiazolylamides which acts by targeting helicase-primase.
AiCuris Anti-infective Cures overview
AiCuris Anti-infective Cures (AiCuris) is a clinical stage biopharmaceutical company that develops novel therapeutic drugs for treating severe infectious diseases in immunocompromised patients. The company carries out research, clinical development and the potential commercialization of anti-infective drugs. Its pipeline products include letermovir (AIC246), which treats allogeneic hematopoietic stem cell (HSC) and kidney transplant patients, and cytomegalovirus infection; pritelivir (AIC316), for acyclovir-resistant herpes simplex virus infections in immunocompromised patients; and AIC468, that targets kidney transplants and bone marrow transplants. AiCuris is headquartered in Wuppertal, Northrhine-Westphalia, Germany.
For a complete picture of Pritelivir mesylate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
